This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McNeel, D. G. Articles by Wilding, G. Search for Related Content PubMed PubMed Citation Articles by McNeel, D. G. Articles by Wilding, G.

Phase I Trial of a Monoclonal Antibody Specific for _vß₃ Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion

Authors' Affiliations:¹ University of Wisconsin Comprehensive Cancer Center; Departments of ² Medicine, ³ Biostatistics, ⁴ Radiology, and ⁵ Pathology; ⁶ School of Pharmacy, University of Wisconsin, Madison, Wisconsin; ⁷ MedImmune Oncology, Inc., Gaithersburg, Maryland; and ⁸ Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland

Requests for reprints: Douglas G. McNeel, Department of Medicine/Medical Oncology, University of Wisconsin Comprehensive Cancer Center, K4/518 Clinical Science Center, 600 Highland Avenue, Madison, WI 53792. Phone: 608-265-8131; Fax: 608-265-8133; E-mail: dm3{at}medicine.wisc.edu.

At present, a variety of agents targeting tumor angiogenesis are under clinical investigation as new therapies for patients with cancer. Overexpression of the _vß₃ integrin on tumor vasculature has been associated with an aggressive phenotype of several solid tumor types. Murine models have shown that antibodies targeting the _vß₃ integrin can affect tumor vasculature and block tumor formation and metastasis. These findings suggest that antibodies directed at _vß₃ could be investigated in the treatment of human malignancies. The current phase I dose escalation study evaluated the safety of MEDI-522, a monoclonal antibody specific for the _vß₃ integrin, in patients with advanced malignancies. Twenty-five patients with a variety of metastatic solid tumors were treated with MEDI-522 on a weekly basis with doses ranging from 2 to 10 mg/kg/wk. Adverse events were assessed weekly; pharmacokinetic studies were done; and radiographic staging was done every 8 weeks. In addition, dynamic computed tomography imaging was done at baseline and at 8 weeks in patients with suitable target lesions amenable to analysis, to potentially identify the effect of MEDI-522 on tumor perfusion. Treatment was well tolerated, and a maximum tolerated dose was not identified by traditional dose-limiting toxicities. The major adverse events observed were grade 1 and 2 infusion-related reactions (fever, rigors, flushing, injection site reactions, and tachycardia), low-grade constitutional and gastrointestinal symptoms (fatigue, myalgias, and nausea), and asymptomatic hypophosphatemia. Dynamic computed tomography imaging suggested a possible effect on tumor perfusion with an increase in contrast mean transit time from baseline to the 8-week evaluation with increasing doses of MEDI-522. No complete or partial responses were observed. Three patients with metastatic renal cell cancer experienced prolonged stable disease (34 weeks, >1 and >2 years) on treatment. With this weekly schedule of administration, and in the doses studied, MEDI-522 seems to be without significant toxicity, may have effects on tumor perfusion, and may have clinical activity in renal cell cancer. These findings suggest the MEDI-522 could be further investigated as an antiangiogenic agent for the treatment of cancer.

This article has been cited by other articles:

				H. L. Goel, J. Li, S. Kogan, and L. R Languino Integrins in prostate cancer progression Endocr. Relat. Cancer, September 1, 2008; 15(3): 657 - 664. [Abstract] [Full Text] [PDF]

				J. K. Willmann, A. M. Lutz, R. Paulmurugan, M. R. Patel, P. Chu, J. Rosenberg, and S. S. Gambhir Dual-targeted Contrast Agent for US Assessment of Tumor Angiogenesis in Vivo Radiology, September 1, 2008; 248(3): 936 - 944. [Abstract] [Full Text] [PDF]

				C.R. Dass, T.M.N. Tran, and P.F.M. Choong Angiogenesis Inhibitors and the Need for Anti-angiogenic Therapeutics J. Dent. Res., October 1, 2007; 86(10): 927 - 936. [Abstract] [Full Text] [PDF]

				S. A. Mullamitha, N. C. Ton, G. J.M. Parker, A. Jackson, P. J. Julyan, C. Roberts, G. A. Buonaccorsi, Y. Watson, K. Davies, S. Cheung, et al. Phase I Evaluation of a Fully Human Anti-{alpha}v Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors Clin. Cancer Res., April 1, 2007; 13(7): 2128 - 2135. [Abstract] [Full Text] [PDF]

				K. Mulgrew, K. Kinneer, X.-T. Yao, B. K. Ward, M. M. Damschroder, B. Walsh, S.-Y. Mao, C. Gao, P. A. Kiener, S. Coats, et al. Direct targeting of {alpha}v{beta}3 integrin on tumor cells with a monoclonal antibody, AbegrinTM Mol. Cancer Ther., December 1, 2006; 5(12): 3122 - 3129. [Abstract] [Full Text] [PDF]

				W. Cai, Y. Wu, K. Chen, Q. Cao, D. A. Tice, and X. Chen In vitro and In vivo Characterization of 64Cu-Labeled AbegrinTM, a Humanized Monoclonal Antibody against Integrin {alpha}v{beta}3 Cancer Res., October 1, 2006; 66(19): 9673 - 9681. [Abstract] [Full Text] [PDF]